Patients with EGFR mutations were included in real-world studies of durvalumab as consolidation therapy for locally advanced NSCLC, with reported frequencies varying by geographic region: 26.2% in Taiwan (Wang 2021) (11), 10.3% in Japan (Tsukita 2021) (12), 9.5% in South Korea (Jung 2020) (13), 2% in the USA (Offin 2020) (14), and 1.8% in France (Avrillon 2021) (15). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.